ChromaDex, Inc. Appoints Curtis Lockshin, Ph.D., to its Board of Directors
IRVINE, Calif., April 4, 2011 /PRNewswire/ --ChromaDex Corporation (OTCBB: CDXC),an innovative natural products company that provides proprietary, science-based solutions and ingredients, today announced that Curtis A. Lockshin, Ph.D., was appointed to its Board of Directors.
Dr. Lockshin currently serves as a Director of Sorrento Therapeutics and the Ruth K. Broad Biomedical Research Foundation, a Duke University Support Corporation. He previously served as a Director of Winston Pharmaceuticals. In addition to his board positions, he serves as a consultant to private companies in healthcare and biotechnology. He initially began his career as a scientist with Sepracor and eventually became the research director responsible for the strategy and operations of Sepracor's new leads initiative. Dr. Lockshin holds a Ph.D. in Biological Chemistry from the Massachusetts Institute of Technology.
"Dr. Lockshin's deep experience with an array of science-based, regulated companies brings valuable perspective to our board," said Frank Jaksch, CEO and co-founder of ChromaDex. "As we convert our knowledge of natural compounds into innovative commercial products and applications targeted at the nutraceutical, food and beverage, cosmetic and pharmaceutical markets, we are committed to strengthening our management team and our board with the experience needed to reinforce our dedication to the science behind our natural ingredients."
About ChromaDex
ChromaDex is an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries. The company has a strong pipeline of new compounds, including its pTeroPure pterostilbene on which it has worldwide, exclusive rights to patents pending. ChromaDex is a publicly-traded life-sciences company (OTC stock symbol CDXC.OB).
Forward-Looking Statements
Any statements that are not historical facts contained in this release are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to: the ability to market, produce and sell the referenced ingredients; risks relating to product and customer demand, market acceptance of our products; the effect of economic conditions both nationally and internationally; the ability to protect our intellectual property rights; the impact of any litigation or infringement actions brought against us; competition from other providers and products; risks in product development; our ability to raise capital to fund continuing operations; the ability to complete transactions; and other factors discussed from time to time in the company's Securities and Exchange Commission filings. The company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.
Investor Inquiries
Liviakis Financial Communications, Inc.
John M. Liviakis, President
415-389-4670
John@Liviakis.com
ChromaDex Contact
Jenny Robles
949-419-0288
jennyr@chromadex.com
Media Contact
Carolyn Hawley
Canale Communications
619-849-5375
carolyn@canalecomm.com
SOURCE ChromaDex Corporation